← Human Trials & Peer-Reviewed Studies
Growth hormone abuse and biological passport: is mannan-binding lectin a complementary candidate?
Plain-language guide to PMID 21814138 (2011): single-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 12 subjects.
Key Facts
- PMID
- 21814138
- Journal
- Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Such-Sanmartín G et al. (4 authors)
- DOI
- 10.1097/JSM.0b013e318221f6e4
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
In the detection of human growth hormone (GH) abuse, the approach based on altered GH-related biomarkers is also being considered with respect to its application within the context of a biological passport.
As a potential biomarker, mannan-binding lectin (MBL), which is reported to respond to recombinant GH (rGH) administration, is evaluated here.
Who Took Part
According to the abstract, 12 subjects were involved.
By PubMed's age tags, the people studied were young adults and adults, men only.
How the Study Was Run
In design terms this was a randomized and single-blind study.
The subjects were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
In this single-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study one party knew the assignments and the other did not.
Randomized and single blind and approved by the Ethical Committee (Comité Ético de Investigación Clínica-Instituto Municipal de Asistencia Sanitaria).
What Was Measured
PubMed files the paper under topics including Biomarkers, Doping in Sports, Human Growth Hormone, Mannose-Binding Lectin, Recombinant Proteins, Substance Abuse Detection and Substance-Related Disorders.
What This Means in Plain Language
The paper is a randomized and single-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 12 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2011 (Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.